August 14, 2025

T1DX-QI Data Governance Committee, Meeting minutes, 8/14/2025

Attendees: Marina Basina, Georgia Davis, Daniel DeSalvo, David Hansen, Grace Nelson, Nicole Rioles, Nicole Sheanon, and Ruth Weinstock

Meeting Slides

• Overview of new projects with funding opportunities
  • BG and Ketone Monitoring (T1D)
    • Potential for T1D plus T2D project
    • Understand value of tool for population
    • Data: PWD (ages TBD); DKA events, ketone monitoring, SGLT-2 medication use; A1c. Potential data (race/ethnicity; public/private insurance
    • Discussion
      • T2D needs as well. Monitoring euglycemia and ketones
      • Research point of interest: measuring rates of ketone (strip) prescribing in peds vs adults
    • Four-five centers will be selected in the next two months. If you are interested in participating in this project, please email QI@t1dexchange.org
  • Inhaled insulin (T1D)
    • Potential for T1D/T2D application
    • Focused on understanding barriers to inhaled insulin prescribing and use
    • 2-3 centers will be selected for 18–65-year-old populations
    • Data: T1D. Age cohort 18+. A1c, inhaled insulin prescribing.
    • Potential data (race/ethnicity; public/private insurance
    • If you are interested in participating in this project, please email QI@t1dexchange.org
• T2D
  • T2D Obesity funding proposal to Novo Nordisk, Timeline of submission: September
    • T2D with Obesity and GLP-1 prescribing application.
    • Data: PwT2D (12 y/o-65); BMI; GLP–1 prescribing; A1c
    • Challenges identified:
      • Hard prescribing: Texas Medicaid does not cover GLP-1 costs
      • Not covered if A1c beloe 7%
    • Group discussed value of individualizing therapy
    • Focus on other reagents
  • T2D and AID use
    • AID use project – proposal to Insulet
    • Timeline of submission (September)
    • Data: T2D. Age cohort tbd. A1c, AID prescribing.
    • Group discussed:
      • Looking at TDD and weight change
      • Challenges with over-insulinizing with MDI (potential goal of reducing with AID)
      • At DX: looking at weaning off insulin after 6 months and sticking with other therapies, like GLP-1s, GLP-1 and SGLT-2, Metformin and GLP-1, bariatric surgery, etc. Have to look at what can be covered.
      • What does success with GLP-1 look like?
      • Value in understand patient preferences and satisfaction as well as provider preferences.
      • Measure % of pt on GLP-1 as well. Track BMI change, DKA change, A1c change, etc.
      • Qualitative interviewing
      • Goal of lowering age of approval
      • What do patients want from it?
      • Eligibility? MDI
      • Discussing of U200 and U500 uses in pumps for pts with low rates of insulin sensitivity
  • Other project suggestions
    • Sequel (Twiist) open to discussions
    • Mattel corp: concept of building financial literacy and independence for young (14-25) people with diabetes
      • Help them navigate and have independence in career development, managing needs for diabetes (accommodates, insurance hurdles, etc.)
  • T1D Exchange is setting goal to map six adult centers for T2D.
    • If any adult center is interested in participating in this, please email QI@t1dexchange.org
    • For reference, please see T2D data specification https://t1dx-qi.t1dexchange.org/data-mapping/
    • Centers that have not completed T2D data mapping can start that process now. Data for proposed projects can be submitted via Smartsheet and do not require data mapping for eligibility
• Next meeting: February 12th from 11 am – 12 pm EST